Research · Sep 3, 2026
[ALKS] Alkermes Thesis 2026: A CNS Pure-Play Pivots Toward Narcolepsy and an Orexin-Class Catalyst
Alkermes plc (NASDAQ: ALKS) is a Dublin, Ireland-headquartered (US operations principally in Waltham, Massachusetts) biopharmaceutical company focused on central-nervous-system (CNS) diseases — developing and commercializing therapies for psychiatric conditions (schizophrenia, bipolar disorder), addiction (opioid and alcohol dependence), and sleep/wakefulness disorders (narcolepsy). The company was founded in 1987 by Richard Pops (Chairman, President & CEO — one of the longest-tenured CEOs in biotech) and has evolved through multiple strategic transformations: a 1990s/2000s focus on drug-delivery technology (long-acting injectable / sustained-release platforms), a 2011 reverse merger with Elan Drug Technologies establishing the current Irish-headquartered structure, a multi-year build of a commercial-stage CNS franchise (VIVITROL launched 2006, ARISTADA 2015, LYBALVI 2021), an oncology-development push that was spun off in late 2023 as Mural Oncology (MURA) to refocus Alkermes as a pure-play CNS company, and the 2022-2024 monetization of various royalty streams (including Sandoz/Aristada-related royalties) generating substantial cash. Today Alkermes runs a focused commercial CNS portfolio plus a CNS-focused pipeline, with the headline pipeline asset ALKS 2680 — an oral orexin-2 receptor agonist for narcolepsy. Capital structure is net-cash with minimal debt and aggressive buyback / capital-return activity. Geography is US-led commercial with selected ex-US partnered. ALKS enters FY2026 with FY2025 revenue selected various aggregate ~$1.55-1.85B, aggregate adjusted EPS ~$2.80-3.50, adjusted EBITDA ~$380-470M (~22-26% margin), under Pops. The first thesis pillar is the commercial CNS franchise — three approved products generating ~$1.1-1.3B+ annually: VIVITROL (extended-release naltrexone, monthly IM, opioid/alcohol dependence — launched 2006, ~$430-490M+, low-single-digit % growth — used in addiction-treatment centers, behavioral-health clinics, drug courts, prison systems, primary care/OBGYN; growth driven by opioid epidemic + LAI-injection advantage vs daily oral naltrexone); ARISTADA (aripiprazole lauroxil, LAI in monthly/bi-monthly/every-2-month options for schizophrenia — launched 2015, ~$330-400M+, low-to-mid-single % growth — competing in the schizophrenia LAI market vs Otsuka/Lundbeck Abilify Maintena, Janssen Invega franchise, Sandoz Risperdal Consta, and generics; differentiates on dosing intervals and aripiprazole-lauroxil pro-drug profile); LYBALVI (oral olanzapine/samidorphan combination for schizophrenia + bipolar I — launched 2021, ~$310-400M+ growing fastest at mid-teens-to-twenties % as long-tail-of-launch plays out — designed to provide olanzapine's strong antipsychotic efficacy while reducing the substantial weight-gain side-effect that has historically limited olanzapine's use, addressing a real unmet need); FY2025 dynamics are VIVITROL/ARISTADA growing steadily, LYBALVI accelerating, gross-to-net stabilizing, operating leverage improving; FY2026 catalyst is LYBALVI prescription growth (leading-edge driver), VIVITROL/ARISTADA share defense, payer/formulary dynamics, generic-aripiprazole pressure on ARISTADA, and operating-margin expansion; risks/competitors are generic competition (LAI mechanisms partially insulate ARISTADA and VIVITROL but pricing pressure persists), newer antipsychotics — especially Bristol-Myers's Cobenfy (KarXT/xanomeline-trospium for schizophrenia approved 2024 — new mechanism competing with antipsychotic class), Otsuka's Rexulti, Janssen's Invega franchise, AbbVie — payer/formulary access, addiction-treatment-system funding fluctuations. The second pillar is ALKS 2680 plus the broader pipeline — the growth optionality: the narcolepsy opportunity — narcolepsy type 1 (NT1) is a rare CNS disorder caused by loss of orexin/hypocretin-producing neurons in the hypothalamus, patients experience excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations, disrupted nighttime sleep; the underlying biology — orexin deficiency — has made orexin replacement the long-pursued holy grail, but orexin peptides are large/cannot cross the BBB easily, so the race has been to develop small-molecule oral orexin-2 receptor agonists; ALKS 2680 — Alkermes's oral once-daily small-molecule orexin-2 receptor agonist in clinical development for NT1 (and potentially NT2 and idiopathic hypersomnia) — Phase 1 and Phase 1b/2 data have shown encouraging effects on wakefulness measures and tolerability, program moving toward Phase 2/3 trials and potential regulatory approval; the competitive landscape — Takeda's TAK-861 (oral orexin-2 receptor agonist) the most advanced competitor in the narcolepsy space with Phase 3 data anticipated (after the earlier TAK-994 program was discontinued for hepatic toxicity, TAK-861 has shown a cleaner profile), Centessa Pharmaceuticals (CNTA) ORX750 in earlier development, Jazz Pharmaceuticals (JAZZ) selling current standard-of-care narcolepsy drugs (Xyrem/Xywav, Sunosi) and developing its own orexin program; FY2025 dynamics are ALKS 2680 Phase 2 trial data continuing to mature with multiple readouts expected, regulatory engagement underway, development advancing; FY2026 catalyst is ALKS 2680 Phase 2 results / Phase 3 initiation / regulatory pathway clarification (the major asymmetric value-creation event — a successful orexin-2 agonist with a clean safety profile could be transformative worth multiple billions in annual revenue across narcolepsy types), plus earlier-stage CNS pipeline programs in psychiatric/neurological/sleep targets; the post-Mural-spin pipeline — after the late-2023 Mural (MURA) oncology spin Alkermes refocused on a CNS-only pipeline; risks are ALKS 2680 Phase 2/3 failure (efficacy or safety/tolerability — orexin-2 agonists need clean liver/safety profile after TAK-994), Takeda TAK-861 first-to-market capturing the franchise, other orexin programs emerging, regulatory pathway uncertainty (narcolepsy a rare disease — orphan-drug designation and accelerated-approval potential exist), CNS R&D risk; comp set is Jazz Pharmaceuticals (JAZZ) the incumbent leader, Takeda (4502.T), Centessa (CNTA), Avadel (AVDL), Harmony Biosciences (HRMY) in narcolepsy/sleep, and broader CNS Axsome (AXSM), Sage (SAGE), Vanda (VNDA), Acadia (ACAD), Intra-Cellular (now J&J). The capital story: net-cash, shareholder-return-rich — recently-initiated/considered dividend (~$0-0.40/share annually — historically none, post-Mural and royalty monetization deploying cash via buybacks + exploring dividend), substantial share buybacks (~155-165M shares down from ~170M+ peak), substantial net cash (~$500-800M+ cash/marketable securities with minimal debt — Elan-merger debt substantially paid down/refinanced), strong FCF (high-margin commercial CNS + modest capex), capital priorities fund R&D (esp. ALKS 2680) → aggressive buybacks → possible dividend → bolt-on M&A or BD → maintain net cash, with cash deployment optionality ($500-800M+ war chest), pipeline R&D spending, and strategic-decision pace under Pops as principal considerations. At ~$28-42 per share on ~155-165M shares (~$4.5-7B equity, ~$3.7-6.2B EV given net-cash) ALKS trades at roughly ~10-15x P/E, ~7-12x EV/EBITDA and ~10-15x EV/FCF — discounted versus where high-growth specialty pharmas trade, reflecting VIVITROL/ARISTADA maturity and modest LYBALVI visibility, but substantial ALKS 2680 upside if it delivers and FCF/balance-sheet downside protection — versus CNS Bristol-Myers (BMY, Cobenfy), Otsuka (4578.T), Lundbeck (LUN.CO), Axsome (AXSM), Sage (SAGE), Vanda (VNDA), Acadia (ACAD), Intra-Cellular (now J&J), narcolepsy Jazz (JAZZ), Avadel (AVDL), Harmony (HRMY), and broader specialty Insmed (INSM), Krystal Biotech (KRYS), Argenx (ARGX), Ultragenyx (RARE), BridgeBio (BBIO). FY2026 base case: ~$1.6-1.9B+ revenue + ~$3.00-3.75 adj. EPS + ~$400-490M adjusted EBITDA + LYBALVI growing + VIVITROL/ARISTADA stable + ALKS 2680 Phase 2 data + continued buybacks + cash building; bull case: ~$1.75-2.1B+ revenue + ~$3.50-4.50+ adj. EPS on stronger LYBALVI growth, share defense, ALKS 2680 Phase 2 clean and supporting Phase 3 / accelerated-approval (major asymmetric upside), accretive M&A, accelerated buybacks, and a re-rating; bear case: ~$1.45-1.65B revenue + ~$2.40-2.90 adj. EPS on a Cobenfy/competitor-take-share scenario, ALKS 2680 failure, Takeda TAK-861 first-to-market, pipeline disappointment, and a compression. The thesis depends on the commercial-CNS pipeline (VIVITROL + ARISTADA + LYBALVI trajectory + payer access + competitive positioning vs Cobenfy and generics) plus the ALKS 2680 + pipeline pipeline (Phase 2 data + Phase 3 path + competitive race with Takeda TAK-861 + broader CNS pipeline) plus the net-cash balance sheet plus aggressive buybacks plus possible bolt-on M&A plus Richard Pops's continued strategic stewardship.